RT @TumorBoardTues
8/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc #EndometrialCancer
Pivotal trials leading to FDA approval in 2L met MSI-H/dMMR #EndometrialCarcinoma
🔸Pembro: #KEYNOTE158 (phase 2)
🔹Dostarlimab: #GARNET (phase 1)
🔑Efficacy & safety data 📷👇
#bonumce #OncTwitter #gyncsm #gynonc #endometrialcancer #endometrialcarcinoma #keynote158 #garnet
8/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc #EndometrialCancer
Pivotal trials leading to FDA approval in 2L met MSI-H/dMMR #EndometrialCarcinoma
🔸Pembro: #KEYNOTE158 (phase 2)
🔹Dostarlimab: #GARNET (phase 1)
🔑Efficacy & safety data 📷👇
#bonumce #OncTwitter #gyncsm #gynonc #endometrialcancer #endometrialcarcinoma #keynote158 #garnet